Peer Review

Alnylam adds a slate of new executives; Thomas Insel is leaving Verily; Akari CEO Gur Roshwalb placed on leave

→ Scott Gottlieb was sworn in as America’s 23rd Commissioner of Food and Drugs yesterday.

→ RNAi biotech Alnylam named a slate of new appointments including Manmeet Soni as CFO, who arrives by way of Ariad and PharmacyclicsTheresa Heggie as senior vice president, head of Europe and Canada; Peter Smith, senior vice president, early development; plus former Celgene and BIO executive Alan Eisenberg as vice president, global public policy and government relations.

→ Akari Therapeutics CEO Gur Roshwalb was placed on administrative leave.

Aravive Biologics named Stephen Eck as its president and CEO.

Thomas Insel is leaving Verily.

Bob Vonderheide is the new director of the Abramson Cancer Center of the University of Pennsylvania.

David Ford is leaving Sanofi Genzyme to join Intercept Pharmaceuticals.



The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,500+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->